Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
about
Challenging hepatitis C-infected liver transplant patientsCost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.'It's been a long haul, a big haul, but we've made it': hepatitis C virus treatment in post-transplant patients with virus recurrence: An interpretative phenomenological analysis
P2860
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
@ast
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
@en
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
@nl
type
label
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
@ast
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
@en
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
@nl
prefLabel
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
@ast
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
@en
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
@nl
P2860
P356
P1476
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
@en
P2860
P304
P356
10.4254/WJH.V7.I24.2543
P407
P50
P577
2015-10-28T00:00:00Z